EMEA-001501-PIP01-13-M07
Key facts
| Invented name |
Dupixent
|
| Active substance |
dupilumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0329/2021
|
| PIP number |
EMEA-001501-PIP01-13-M07
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of atopic dermatitis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Regeneron Pharmaceuticals Inc
E-mail: clinicaltrials@regeneron.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001501-PIP01-13-M07
|
| Compliance opinion date |
25/02/2022
|
| Compliance outcome |
positive
|